ANAHEIM, Calif., July 26 /PRNewswire-FirstCall/ — A
first-of-its-kind test that detects HIV infection earlier than ever
before in the United States; a
molecular assay for identification of two common sexually
transmitted diseases; and an enhanced integrated analyzer offering
significant workflow improvements; are among the many new advances
Abbott (NYSE: ABT) will highlight at this year’s American
Association for Clinical Chemistry Lab Expo (AACC) which starts
today in Anaheim. In all, Abbott
is sponsoring 29 scientific posters reporting on new clinical
diagnostics research in areas such as heart disease or cardiac
care, transplant, renal disease and cancer; three scientific
industry workshops; and 15 main stage presentations at the Abbott
exhibit booth (#6808).
“Abbott is focused on improving patient care by offering
innovative solutions for our laboratory customers and the patients
and physicians they serve,” said Brian
Blaser, senior vice president, Diagnostics, Abbott. “At this
year’s AACC, we will feature our latest assays and systems which
offer solutions to meet the demanding needs of healthcare
institutions by improving operational efficiency, clinical
outcomes, and physician, patient, and laboratory satisfaction.”
Abbott AACC Highlights
- Advances in HIV Testing Foster Early Detection: Last
month, the FDA approved Abbott’s ARCHITECT HIV Antigen/Antibody
Combo Assay, a first-of-its-kind new HIV diagnostic tool. Since the
test detects both HIV antigens and antibodies, Abbott’s test can
identify infection days earlier than other an‘/>”/>
